Want to join the conversation?
3Q15 R&D expense was $520MM or 19% of revenues for $BIIB, including $48MM in upfront milestone expense related to a closed collaboration with AGTC. 3Q15 SG&A expense was $478MM or 17% of revenue. $BIIBâ??s current expectation is to complete the $5Bil share repurchase program by year end. In mid-Sept. $BIIB borrowed $6Bil of senior unsecured notes.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.